ABL Diagnostics Shares Bounce Back After New Contract Through 2031
The stock of the molecular diagnostics company is regaining ground in this Friday's session, supported by the announcement of a new multi-year commercial agreement. However, the rebound remains modest in light of a still deteriorated stock market performance over recent months.
A Multi-Year Contract Through 2031 Boosts the Session
ABL Diagnostics' stock is up 2.33% at €2.64 in early afternoon trading, in a well-oriented Parisian market (the CAC 40 is up 1.79% and the SBF 120 1.75%). The stock is benefiting from the announcement, this Friday, of the signing of a multi-year contract with a European pharmaceutical laboratory specializing in neurodegenerative diseases. The agreement, managed by sister company CDL Pharma, runs until 2031 and could be worth up to €2.7 million. This announcement is part of an active period for the group, which also submitted a takeover bid for Texcell on June 9, as part of its external growth strategy in molecular diagnostics.
A Rebound That Only Marginally Corrects a Deteriorated Stock Market Performance
Today's movement does not change the underlying trend: the stock is still down nearly 9% for the week and has lost more than 17% over three months, with a decline of 51% over a year. The price continues to trade significantly below its three moving averages, with a gap of nearly 18% below the MM20 (€3.21) and nearly 25% below the MM200 (€3.51), reflecting an ongoing bearish dynamic at this stage. The RSI at 40 remains in the neutral zone, with no marked exhaustion of selling pressure; support is at €2.22 and the stock remains well above this level. Investors will monitor the group's ability to realize the 76.5% growth guidance for 2026 communicated at the beginning of June.
